Cargando…

Nuclear Medicine Imaging in Neuroblastoma: Current Status and New Developments

Neuroblastoma is the most common extracranial solid malignancy in children. At diagnosis, approximately 50% of patients present with metastatic disease. These patients are at high risk for refractory or recurrent disease, which conveys a very poor prognosis. During the past decades, nuclear medicine...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samim, Atia, Tytgat, Godelieve A.M., Bleeker, Gitta, Wenker, Sylvia T.M., Chatalic, Kristell L.S., Poot, Alex J., Tolboom, Nelleke, van Noesel, Max M., Lam, Marnix G.E.H., de Keizer, Bart
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066332/ https://www.ncbi.nlm.nih.gov/pubmed/33916640 http://dx.doi.org/10.3390/jpm11040270

Ejemplares similares

[(18)F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2022)

Correction to: [(18)F]mFBG PET‑CT for detection and localisation of neuroblastoma: a prospective pilot study
por: Samim, Atia, et al.
Publicado: (2023)

123I‐MIBG scintigraphy and 18F‐FDG‐PET imaging for diagnosing neuroblastoma
por: Bleeker, Gitta, et al.
Publicado: (2015)

The role of (131)I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma
por: Schoot, Reineke A., et al.
Publicado: (2013)

Toxicity of upfront (131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy in newly diagnosed neuroblastoma patients: a retrospective analysis
por: Bleeker, Gitta, et al.
Publicado: (2013)

The Current Status and Future Potential of Theranostics to Diagnose and Treat Childhood Cancer
por: Poot, Alex J., et al.
Publicado: (2020)

MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis
por: Bleeker, Gitta, et al.
Publicado: (2014)

Treatment-Related Toxicities During Anti-GD2 Immunotherapy in High-Risk Neuroblastoma Patients
por: Blom, Thomas, et al.
Publicado: (2021)

Mesenchymal Stromal Cells in Neuroblastoma: Exploring Crosstalk and Therapeutic Implications
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Imaging in neuroblastoma
por: Littooij, Annemieke S., et al.
Publicado: (2022)

Mesenchymal Neuroblastoma Cells Are Undetected by Current mRNA Marker Panels: The Development of a Specific Neuroblastoma Mesenchymal Minimal Residual Disease Panel
por: van Wezel, Esther M., et al.
Publicado: (2019)

IMG-04. POTENTIAL TARGETS FOR THERANOSTICS IN PEDIATRIC HIGH-GRADE CENTRAL NERVOUS SYSTEM (CNS) TUMORS
por: Plasschaert, Sabine, et al.
Publicado: (2023)

The Potential of Mesenchymal Stromal Cells in Neuroblastoma Therapy for Delivery of Anti-Cancer Agents and Hematopoietic Recovery
por: Hochheuser, Caroline, et al.
Publicado: (2021)

Fenretinide induces mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma
por: Cuperus, Roos, et al.
Publicado: (2009)

Anti-GD2 Based Immunotherapy Prevents Late Events in High-Risk Neuroblastoma Patients over 18 Months at Diagnosis
por: Tas, Michelle L., et al.
Publicado: (2021)

Evaluation of FDG-PET/CT Use in Children with Suspected Infection or Inflammation
por: Ropers, Fabienne G., et al.
Publicado: (2020)

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma
por: Eleveld, Thomas F., et al.
Publicado: (2023)

Systems Radiology and Personalized Medicine
por: Foppen, Wouter, et al.
Publicado: (2021)

Optimal timing of interictal FDG‐PET for epilepsy surgery: A systematic review on time since last seizure
por: de Laat, Nienke N., et al.
Publicado: (2022)

CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather
por: Jacobs, Sarah M., et al.
Publicado: (2021)

Refractory Stage M Ganglioneuroblastoma With Bone Metastases and a Favorable, Chronic Course of Disease: Description of a Patient Cohort
por: Tas, Michelle L., et al.
Publicado: (2022)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

The Metastatic Bone Marrow Niche in Neuroblastoma: Altered Phenotype and Function of Mesenchymal Stromal Cells
por: Hochheuser, Caroline, et al.
Publicado: (2020)

Mutational spectrum of ATRX aberrations in neuroblastoma and associated patient and tumor characteristics
por: van Gerven, Michael R., et al.
Publicado: (2022)

Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [(11)C]PiB
por: Heeman, Fiona, et al.
Publicado: (2021)

Selective serotonin reuptake inhibitors (SSRIs) prevent meta-iodobenzylguanidine (MIBG) uptake in platelets without affecting neuroblastoma tumor uptake
por: Blom, Thomas, et al.
Publicado: (2020)

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma
por: Keller, Kaylee M., et al.
Publicado: (2022)

Specific and Sensitive Detection of Neuroblastoma mRNA Markers by Multiplex RT-qPCR
por: van Zogchel, Lieke M. J., et al.
Publicado: (2021)

Test-retest variability of quantitative [(11)C]PIB studies in Alzheimer’s disease
por: Tolboom, Nelleke, et al.
Publicado: (2009)

[(11)C]PIB amyloid quantification: effect of reference region selection
por: Heeman, Fiona, et al.
Publicado: (2020)

Thrombocytopenia after meta-iodobenzylguanidine (MIBG) therapy in neuroblastoma patients may be caused by selective MIBG uptake via the serotonin transporter located on megakaryocytes
por: Blom, Thomas, et al.
Publicado: (2021)

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

Cell-Free RNA from Plasma in Patients with Neuroblastoma: Exploring the Technical and Clinical Potential
por: Lak, Nathalie S. M., et al.
Publicado: (2023)

Urinary 3-Methoxytyramine Is a Biomarker for MYC Activity in Patients With Neuroblastoma
por: Verly, Iedan R. N., et al.
Publicado: (2022)

Hypermethylated RASSF1A as Circulating Tumor DNA Marker for Disease Monitoring in Neuroblastoma
por: van Zogchel, Lieke M. J., et al.
Publicado: (2020)

Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease
por: Lak, Nathalie S.M., et al.
Publicado: (2021)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

Natural killer cells facilitate PRAME-specific T-cell reactivity against neuroblastoma
por: Spel, Lotte, et al.
Publicado: (2015)

Whole-body MRI versus an [(18)F]FDG-PET/CT-based reference standard for early response assessment and restaging of paediatric Hodgkin’s lymphoma: a prospective multicentre study
por: Spijkers, Suzanne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6osj67if6rdt4agj6frma19kd9